Fujimura A, Kajiyama H, Ebihara A, Iwashita K, Nomura Y, Kawahara Y
Nephron. 1986;44(4):324-8. doi: 10.1159/000184014.
Pharmacokinetics and pharmacodynamics of captopril were studied in 5 continuous ambulatory peritoneal dialysis (CAPD) patients (including 2 hypertensive patients) after single oral administration of 50 mg captopril. The pharmacokinetic parameters for plasma free unchanged captopril were time to maximal concentration 1.1 +/- 0.3 h, maximal plasma concentration 387 +/- 75 ng X ml-1, elimination half-life 1.0 +/- 0.3 h, and the area under the concentration-time curve 711 +/- 144 ng X h X ml-1. For plasma total captopril (the sum of free unchanged captopril and its disulfide compounds) the values were time to maximal concentration 3.5 +/- 0.6 h and maximal plasma concentration 2,777 +/- 429 ng X ml-1. Captopril was detected in the dialysis fluid in all CAPD patients. Blood pressures in the 2 hypertensive CAPD patients were lower at 24 h after than before captopril administration. These results suggest that captopril may be eliminated by CAPD. In addition, there is a possibility that the antihypertensive effects of captopril may be prolonged in hypertensive CAPD patients.
对5例持续性非卧床腹膜透析（CAPD）患者（包括2例高血压患者）单次口服50毫克卡托普利后，研究了卡托普利的药代动力学和药效学。血浆中游离未变化卡托普利的药代动力学参数为：达峰时间1.1±0.3小时，最大血浆浓度387±75纳克×毫升⁻¹，消除半衰期1.0±0.3小时，浓度-时间曲线下面积711±144纳克×小时×毫升⁻¹。对于血浆总卡托普利（游离未变化卡托普利及其二硫化物化合物的总和），其值为达峰时间3.5±0.6小时和最大血浆浓度2777±429纳克×毫升⁻¹。所有CAPD患者的透析液中均检测到卡托普利。2例高血压CAPD患者给药后24小时的血压低于给药前。这些结果表明卡托普利可能通过CAPD被清除。此外，卡托普利对高血压CAPD患者的降压作用有可能会延长。
